Bioprocess360 Partners Launch Dedicated Life Sciences Investment Fund To Grow Emerging Bioprocessing Tools And Technologies

By Author: Orson Amiri
Total Articles: 413
Comment this article

BioProcess360 Partners has launched a new investment fund aimed at supporting businesses in advancing bioprocessing technologies for both traditional monoclonal antibodies (mAbs) and newer drug modalities. Led by industry veterans Chris Major and Bradford Beatty, the fund provides capital alongside expertise and connections to global biopharmaceutical companies. Chris Major, drawing from his experience in guiding Purolite Bioprocessing, emphasizes the fund's role in addressing critical R&D and commercialization challenges through hands-on industry support.

The fund focuses on bridging gaps in the bioprocessing sector by offering direct access to seasoned experts across R&D, manufacturing, regulatory compliance, and commercial operations. With a team of 14 specialists, BioProcess360 Partners aims to accelerate innovation and revenue generation for emerging bioprocessing technologies. Chris Major highlights their proactive approach in filling market needs for collaborative partners who specialize in nurturing bioprocessing innovations, ensuring rapid deployment of funding and resources to foster business success in this specialized field.

Read More - https://www.techdogs.com/tech-news/globe-newswire/bioprocess360-partners-launch-dedicated-life-sciences-investment-fund-to-grow-emerging-bioprocessing-tools-and-technologies